Loading stock data…
Alnylam Pharmaceuticals, Inc. (ALNY)
$266.11+1.61 (+0.61%)
Pre-Market$252.46-13.65 (-5.13%)· Last close Sep 4
Alnylam Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alnylam Pharmaceuticals, Inc. in the Healthcare sector is trading at $266.11 with a market capitalization of $30.6B. Wall Street consensus targets $370.20 (26 analysts), implying a +39.1% move over the next 12 months. The stock is currently 46% below its 52-week high of $495.55, remaining 17.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 76 is overbought against a weak tape. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +39.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 76 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.29B↑ | $1.17B↑ | $1.10B↓ | $1.25B↑ | $773.69M |
| Gross Profit | $992.50M↑ | $956.05M↑ | $829.31M↓ | $1.05B↑ | $630.74M |
| Operating Income | $231.44M↓ | $268.64M↑ | $131.72M↓ | $367.98M↑ | -$16.20M |
| Net Income | $164.49M↓ | $205.99M↑ | $186.42M↓ | $251.08M↑ | -$72.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.78
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
59.67%
Volume
Today's trading volume
1.43M
Recent News
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.